Vincerx Pharma, Inc. (VINC)
| Market Cap | 236.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.81M |
| Shares Out | 16.35M |
| EPS (ttm) | -2.42 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42,782 |
| Open | 13.37 |
| Previous Close | 13.37 |
| Day's Range | 13.37 - 14.07 |
| 52-Week Range | 11.00 - 26.75 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 29.75 (+112.5%) |
| Est. Earnings Date | n/a |
About VINC
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops new therapies to address unmet medical needs for the treatment of cancer. The company's lead product candidate is VIP152 that is in Phase I clinical trials to treat solid tumors. Its preclinical stage product candidates include VIP217 for solid tumors; VIP236 to treat multiple solid tumors; VIP943 for the treatment of leukemia and myelodysplastic syndrome; and VIP924 for treating B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Pal...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for Vincerx Pharma stock is "Strong Buy" and the 12-month stock price forecast is 29.75.
News
Vincerx Pharma Announces $50 Million Private Placement
Strengthened financial position extends expected cash runway into 2023 Strengthened financial position extends expected cash runway into 2023
Vincerx Pharma Reports Second Quarter 2021 Financial Results and Provides a Corporate Update
First patient dosed in Phase 1b study of VIP152 in MYC-driven relapsed or refractory aggressive lymphomas and advanced solid tumors
4 Stocks With CEO Buys in the Past Month
According to the CEO Buys Screen, a Premium All-in-One Screener template, four stocks that had at least three insider buys including the CEO during the past month are REV Group Inc. ( REVG , Financial),...
UPDATE -- Vincerx Pharma Presents Clinical Data on VIP152, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymp...
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at AS...
VIP152 shows favorable safety, on-target pharmacodynamics and signs of durable metabolic complete responses in monotherapy setting
Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggress...
First patient dosed by Vincerx marks significant milestone in Company's development First patient dosed by Vincerx marks significant milestone in Company's development
Vincerx Pharma to Participate in the Jefferies Virtual Healthcare Conference
PALO ALTO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-...
Vincerx Pharma Reports First Quarter 2021 Financial Results and Provides a Corporate Update
Phase 1b dose escalation study of VIP152 in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
Vincerx Pharma Announces FDA Clearance of IND for Phase 1b Study of VIP152 in Chronic Lymphocytic Leukemia and Richte...
Dose escalation study in patients with CLL relapsed/refractory to venetoclax and BTK inhibitors on track to initiate in 2H2021
Vincerx Pharma Presents Preclinical Data on VIP236, its Lead Small Molecule Drug Conjugate, at the American Associati...
VIP236 shows enhanced tumor targeting with robust antitumor activity across multiple xenograft models
Vincerx Pharma To Host Key Opinion Leader Webinar on Bioconjugation and CDK9 Inhibitors for the Treatment of Hematolo...
PALO ALTO, Calif., April 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
Vincerx Pharma Announces Redemption of Public Warrants
PALO ALTO, Calif., April 05, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) (the “Company”), today announced that it will redeem all of its outstanding public warrants (the “Public Warrant...
Vincerx Pharma Announces Formation of Scientific Advisory Board to Advance its Clinical Pipeline
PALO ALTO, Calif., April 01, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
Vincerx Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
License agreement with Bayer AG secures oncology portfolio including clinical-stage PTEFb/CDK9 inhibitor with encouraging Phase 1 activity
Vincerx Pharma Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021
PALO ALTO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradig...
Vincera Pharma Announces Name Change to Vincerx
PALO ALTO, Calif., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm...
Vincera Pharma Announces Completion of Business Combination and Listing on Nasdaq
Business combination transaction with LifeSci Acquisition Corp. was completed on December 23, 2020